Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection

IDrugs

Volumn 13, Issue 3, 2010, Pages 181-191

  Duraffour, Sophie ^a   Andrei, Graciela ^a   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; SIGA 246; SMALLPOX VACCINE; SRI 21950; ST 246; TECOVIRIMAT; TTP 018; UNCLASSIFIED DRUG; VACCINIA ANTIBODY; VIRUS ENVELOPE PROTEIN;

ABNORMAL SENSATION; AREA UNDER THE CURVE; BACKACHE; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG SYNTHESIS; ENCEPHALITIS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOGENICITY; MAXIMUM PLASMA CONCENTRATION; MONKEYPOX; NEUTROPENIA; NONHUMAN; PASSIVE IMMUNIZATION; PATENT; RETINITIS; REVIEW; SINGLE DRUG DOSE; SMALLPOX; SMALLPOX VIRUS; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; VACCINATION REACTION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; BIOLOGICAL WARFARE; CIVIL DEFENSE; DRUG EVALUATION, PRECLINICAL; HUMANS; ISOINDOLES; PATENTS AS TOPIC; SMALLPOX; SMALLPOX VACCINE; TREATMENT OUTCOME; VARIOLA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 77749327477     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Clinical responses to undiluted and diluted smallpox vaccine. Frey SE, Couch RB, Tacket CO, Treaner JJ, Wolf M, Newman FK, Atmar RL, Edelman R, Nolan CM, Belshe RB N ENGL J MED 2002 346 17 1265-1274
2. SIGA announces agreement with ViroPharma to purchase biodefense assets. SIGA Technologies Inc PRESS RELEASE 2004 June 10
3. ViroPharma announces agreement with SIGA Technologies for sale of biodefense assets. ViroPharma Inc PRESS RELEASE 2004 August 25
4. ST-246: A potent and specific inhibitor of orthopoxvirus replication. Jordan R, Yang G, Laquerre S, Barone L, Pevear DC, Bailey TR, Rippin S, Collett MS, de Clercq E, Neyts J, Jones KF ef al ANTIVIR RES 2005 65 3 Abs 14
5. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, Nichols R, Balser JP, Currie M, Monath TP VACCINE 2005 23 25 3301-3309
6. FDA approves SIGA's investigational new drug application for its smallpox drug SIGA-246. SIGA Technologies Inc PRESS RELEASE 2005 December 13
7. Comparison of the pharmacodynamics of cidofovir and ST-246. McSharry JJ, Zager K, Weng Q, Jordan R, Hruby D, Drusano GL ICAAC 2005 45 Washington Abs A-460
8. Activity of ST-246 against vaccinia virus (VACV) and cowpox virus (CPV) in primary human keratinocytes (PHKs) monolayers and organotypic raft cultures. Duraffour S, Snoeck R, van den Oord J, Crance J, Garin D, Jordan R, de Clercq E, Andrei G ICAAC 2006 46 San Francisco Abs V-1480
9. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. Andrei G, Gammon DB, Fiten P, de Clercq E, Opdenakker G, Snoeck R, Evans DH J VIROL 2006 80 19 9391-9401
10. FDA approves orphan drug designation for SIGA's smallpox drug, SIGA-246 the designation is for both treatment and prevention of smallpox. SIGA Technologies Inc PRESS RELEASE 2006 December 20
11. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Quenelle DC, Buller RML, Parker S, Keith KA, Hruby DE, Jordan R, Kern ER ANTIMICROB AGENTS CHEMOTHER 2007 51 2 689-695
12. The combination of anti-poxvirus compounds ST-246 and TTP-018 are synergistic in vitro Chen Y, Harver C, Yang G, Hruby D, Andrews R, Jordan R INT CONF ANTIVIRAL RES 2007 74 3 Abs 140
13. Combinations of CMX-001 and ST-246 synergistically inhibit orthopoxvirus replication in vitro. Keith K, Kern E, Sanders S, Conley R, Jordan R, Hruby D, Painter G, Prichard M INT CONF ANTIVIRAL RES 2007 74 3 Abs 127
14. Successful treatment in the monkeypox and variola primate models of smallpox by the oral drug ST-246. Huggins J, Goff A, Eric M, Twenhafel N, Chapman J, Tate M, Jordan R, Bolken T, Hruby D ANTIVIRAL RES 2007 74 3 Abs 20
15. Efficacy of delayed therapy using combinations of ST-246 with CMX-001 against systemic cowpox virus infections in mice. Quenelle D, Prichard M, Keith K, Collins D, Jordan R, Hruby D, Painter G, Robertson A, Kern E ANTIVIRAL RES 2007 74 3 Abs 105
16. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Sbrana E, Jordan R, Hruby DE, Mateo RI, Xiao SY, Siirin M, Newman PC, DaRossa AP, Tesh RB AM J TROP MED HYG 2007 76 4 768-773
17. N-(3,3a,4,4a,5,5a, 6,6a-octahydro-1,3-dioxo-4,6-etheno-cycloprop[f] isoindol-2-(1H)-ylcarboxamides: Identification of novel orthopoxvirus egress inhibitors. Bailey TR, Rippin SR, Opsitnick E, Burns CJ, Pevear DC, Collett MS, Rhodes G, Tohan S, Huggins JW, Baker RO, Kern ER ef all MED CHEM 2007 50 7 1442-1444
18. Antiviral efficacy of ST-246 in a ground squirrel model of severe monkeypox virus infection. Byrd C, Sbrana E, Xiao SY, Siirin M, Tesh R, Hruby D, Jordan R ANTIVIR RES 2006 70 1 Abs 93
19. Characterization of virus variants resistant to the antiviral effects of ST-246. Yang G, Harver C, Hruby D, Jordan R ANTIVIR RES 2006 70 1 Abs 79
20. ST-246 inhibits vaccinia virus IMV wrapping in the intracellular vesicles. Chen Y, Yang G, Honeychurch K, Hruby D, Jordan R ANTIVIR RES 2006 70 1 Abs 77
21. Evaluation of ST-246 in vaccinia or cowpox virus infections of mice. Kern E, Keith K, Jordan R, Hruby D, Quenelle D ANTIVIR RES 2006 70 1 Abs 29
22. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW ef al J VIROL 2005 79 20 13139-13149
23. ST-246 in vitro efficacy against orthopoxvirus variola and orthopoxvirus monkeypox. Smith SK, Olson VA, Karem KL, Hruby DE, Jordan R, Damon IA ICAAC 2007 47 September 18 Abs F1-953
24. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER ANTIMICROB AGENTS CHEMOTHER 2007 51 11 4118-4124
25. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Duraffour S, Snoeck R, de Vos R, van den Oord JJ, Crance JM, Garin D, Hruby DE, Jordan R, de Clercq E, Andrei G ANTIVIR THER 2007 12 8 1205-1216
26. SIGA files application supporting emergency use approval for ST-246. SIGA Technologies Inc PRESS RELEASE 2008 March 24
27. SIGA advances ST-246 smallpox antiviral development in Europe. SIGA Technologies Inc PRESS RELEASE 2008 April 15
28. Antiviral potency of ST-246 on the production of enveloped orthopoxviruses and characterization of ST-246 resistant vaccinia, cowpox and camelpox viruses. Duraffour S, Vigne S, Gracel A, Jordan R, Hruby DE, Crance JE, Garin D, Andrei G, Snoeck D ANTIVIRAL RES 2008 78 2 Abs 35
29. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Jordan R, Jones K, Bolken T, Tien D, Strasser J, Shanthakumar TR, Frimm A, Corrado M, Strome P, Hruby D ANTIVIRAL RES 2008 78 2 Abs 41
30. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J, Frimm A, Corrado ML, Strome PG, Hruby DE ANTIMICROB AGENTS CHEMOTHER 2008 52 5 1721-1727
31. IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection. Jones T CURR OPIN MOL THER 2008 10 4 407-417
32. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, Hruby DE, Jordan R ANTIVIR RES 2008 79 2 121-127
33. SIGA technologies awarded $55 million by federal government to develop broader applications for its lead drug candidate ST-246. SIGA Technologies Inc PRESS RELEASE 2008 September 03
34. In vitro efficacy of ST246 against smallpox and monkeypox. Smith SK, Olson VA, Karem KL, Jordan R, Hruby DE, Damon IK ANTIMICROB AGENTS CHEMOTHER 2009 53 3 1007-1012
35. Combinations of 5-iodo-4′-thio-2′-deoxyuridine and ST-246 or CMXOOl synergistically inhibit orthopoxvirus replication in vitro. Keith K, Sanders S, Tiwari K, Maddry J, Secrist J, Jordan R, Hruby D, Lanier R, Painter G, Kern E, Prichard M ANTIVIRAL RES 2009 82 2 Abs 58
36. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: Determination of the minimal effective dose and human dose justification. Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, Johnson W ef al ANTIMICROB AGENTS CHEMOTHER 2009 53 5 1817-1822
37. Post-exposure administration with ST-246 prevents the development of severe rabbitpox disease in NZW rabbits. Babas T, Gong K, Sites D, Nieves-Duran LV, Wright R, Rippeon A, Golightly D, Donnelly G, Rhodes L, Hordan R, Hruby D ef al INT CONF ANTIVIRAL RES 2009 22 May 07 LB-11
38. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, Karem K ef al ANTIMICROB AGENTS CHEMOTHER 2009 53 6 2620-2625
39. Characterization of mutations in the F13L gene of orthopoxviruses (OPVs) conferring resistance to ST-246. Duraffour S, Snoeck R, Fiten P, Hruby DE, Jordan R, Opdenakker G, Andrei G ICAAC 2009 49 September 14 Abs V-1759
40. Safety, pharmacokinetics, and human dose justification for ST-246: A novel egress inhibitor being developed for treatment of pathogenic orthopoxvirus infections Jordan R, Tyavanagimatt SR, Amantana A, Chinsangaram L, Bolken TC, Tien D, Jones KF, Frimm A, Corrado ML, Marbury TC, Pickens M ef al ICAAC 2009 49 September 13 Abs A1-593
41. SIGA technologies receives a $3 million research grant from the national institutes of health. SIGA Technologies Inc PRESS RELEASE 2009 September 02
42. ST-246 used to treat complications from exposure to recombinant vaccinia virus. SIGA Technologies Inc PRESS RELEASE 2009 September 15
43. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Chen Y, Honeychurch KM, Yang G, Byrd CM, Harver C, Hruby DE, Jordan R VIROLOGY J 2009 6 44
44. Dramatic rescue relieves rare case of smallpox infection. Marris E NAT MED 2007 13 5 517-517
45. Adverse event related to smallpox vaccination. Bristol N DISASTER MED PUBLIC HEALTH PREP 2007 1 1 11-12
46. Specific targeting of the F13I protein by ST-246 affects orthopoxvirus production differently. Duroffour S, Vigne S, Vermeire K, Garcel A, Vanstreels E, Daelemans D, Yang G, Jordon R, Hruby DE, Crance JM, Garin D et al ANTIVIR THER 2008 13 8 977-990
47. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, Stein SL, Gerber SI, Garcia-Houchins S, Lederman E, Hruby D, Collins L et al CLIN INFECT DIS 2008 46 10 1555-1561
48. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Grosenbach DW, Jordan R, King DS, Berhanu A, Warren TK, Kirkwood-Watts DL, Tyavanagimatt S, Tan Y, Wilson RL, Jones KF, Hruby DE VACCINE 2008 26 7 933-946
49. Smallpox vaccination and adverse reactions. Guidance for clinicians. Cono J, Casey CG, Bell DM, Centers DCP MORBID MORTAL WKLY REP 2003 52 RR-4 1-28
50. Smallpox vaccination: A review, part II. Adverse events. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA CLIN INFECT DIS 2003 37 2 251-271
51. WHO advisory committee on variola virus research: Report of the tenth meeting Geneva, Switzerland 19-20 November 2008. World Health Organization INTERNET SITE 2009 February 23
52. Smallpox fact sheet - Information for clinicians Smallpox (vaccinia) vaccine contraindications. Centers for Disease Controls and Prevention INTERNET SITE 2007 February 07
53. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Berhanu A, King DS, Mosier S, Jordan R, Jones KF, Hruby DE, Grosenbach DW ANTIMICROB AGENTS CHEMOTHER 2009 53 12 4999-5009
54. Household transmission of vaccinia virus from contact with a military smallpox vaccinee - Illinois and Indiana, 2007. MMWR MORB MORTAL WKLY REP 2007 56 19 478-481
55. Eczema vaccinatum: Successful outcome with an intensive therapeutic approach. Hruby D, Vora S, Damon I, Fulginiti V, Kahana M, Marcinak J, Ev RT ABS INTERSCI CONF ANTIMICRO AGENTS CHEMO 2007 47 Abs V-1910
56. Chapter 84: Poxviridae: The viruses and their replication. Moss B FIELDS VIROL 4TH ED (EDS: KNIPE DM; ET AL) 2001 Lippincott Williams and Wilkins, Philadelphia. 4th Edition 2849-2883
57. The Soviet Union's anti-agricultural biological weapons. Alibek K ANN NY ACAD SCI 1999 894 18-19
58. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA J VIROL 2001 75 3 1205-1210
59. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Karem KL, Reynolds M, Hughes C, Braden Z, Nigam P, Crotty S, Glidewell J, Ahmed R, Amara R, Damon IK CLIN VACCINE IMMUNOL 2007 14 10 1318-1327
60. Immunity from smallpox vaccine persists for decades: A longitudinal study. Taub DD, Ershler WB, Janowski M, Artz A, Key ML, McKelvey J, Muller D, Moss B, Ferrucci L, Duffey PL, Longo DL AM J MED 2008 121 12 1058-1064
61. Human monkeypox: An emerging zoonosis. Di Giulio DB, Eckburg PB LANCET INFECT DIS 2004 4 1 15-25
62. Human monkeypox: An emerging zoonotic disease. Parker S, Nuara A, Buller RML, Schultz DA FUTURE MICROBIOL 2007 2 1 17-34
63. Vaccinia virus vaccines: Past, present and future. Jacobs BL, Langland JO, Kibler KV, Denzier KL, White SD, Holechek SA, Wong S, Huynh T, Baskin CR ANTIVIR RES 2009 84 1 1-13
64. Immunogenicity of recombinant modified vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Grandpre LE, Duke-Cohan JS, Ewald BA, Devoy C, Barouch DH, Letvin NL, Reinherz EL, Baden LR, Dolin R, Seaman MS VACCINE 2009 27 10 1549-1556
65. Progressive vaccinia in a military smallpox vaccinee - United States, 2009. Centers DCPCDC MMWR MORB MORTAL WKLY REP 2009 58 19 532-536
66. The acyclic nucleoside phosphonates from inception to clinical use: Historical perspective. de Clercq E ANTIVIR RES 2007 75 1 1-13
67. Topical cidofovir for severe molluscum contagiosum. Davies EG, Thrasher A, Lacey K, Harper J LANCET 1999 353 9169 2042
68. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Meadows KP, Tyring SK, Pavia AT, Rallis TM ARCH DERMATOL 1997 133 8 987-990
69. Topical cidofovir for molluscum contagiosum in children. Zabawski EJ, Cockerell CJ PEDIATR DERMATOL 1999 16 5 414-415
70. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR, Hostetler KY ANTIMICROB AGENTS CHEMOTHER 2002 46 4 991-995
71. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Beadle JR, Hartline C, Aldern KA, Rodriguez N, Harden E, Kern ER, Hostetler KY ANTIMICROB AGENTS CHEMOTHER 2002 46 8 2381-2386
72. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR, Hostetler KY ANTIVIR RES 2003 59 3 163-171
73. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-dalton outer envelope protein. Blasco R, Moss B J VIROL 1991 65 11 5910-5920
74. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. Blasco R, Moss B J VIROL 1992 66 7 4170-4179
75. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. Payne LG J GEN VIROL 1980 50 1 89-100
76. Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. Wolffe EJ, Isaacs SN, Moss B J VIROL 1993 67 8 4732-4741
77. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. Murray JL, Mavrakis M, McDonald NJ, Yilla M, Sheng JS, Bellini WJ, Zhao LJ, Le Doux JM, Shaw MW, Luo CC, Lippincott-Schwartz J et al J VIROL 2005 79 18 11742-11751
78. Chapter 85: Poxviruses. Esposito JJ, Fenner F FIELDS VIROL 4TH ED (EDS: KNIPE DM; ET AL) 2001 Lippincot Williams & Wilkins, Philadelphia, PA, US 4th Edition 2885-2921
79. Chapter 134: Orthopoxviruses: Vaccinia (smallpox vaccine), variola (smallpox), monkeypox, and cowpox. Damon IK MANDELL, DOUGLAS, BENNETTS PRINCIPLES PRACT INFECT DIS (EDS: MANDELL GL, BENNETT JE, DOLIN R) 2010 Churchill Livingstone, New York, NY, USA 7th Edition 1923-1932
80. Chapter 18: Therapy of poxvirus infections. Snoeck R, Andrei G, de Clercq E POXVIRUSES: BIRKHAUSER ADV INFECT DIS (EDS: MERCER A, SCHMIDT A, WEBER O) 2007 Birkhauser Verlag AG, Basel, Switzerland 375-396
81. Chapter 1: Genu Orthopoxvirus: Vaccinia virus. Smith GL POXVIRUSES: BIRKHAUSER ADV INFECT DIS (EDS: MERCER A, SCHMIDT A, WEBER O) 2007 Birkhauser Verlag AG, Basel, Switzerland 1-45
82. Specific inhibition of orthopoxvirus replication by small interfering RNA: Involvement in the mechanistic of ST-246. Duraffour S, Vigne S, Snoeck R, Vermeire K, Vanstreels E, Daelemans D, Yang G, Jordan R, Hruby D, Crance JM, Garin D ef al INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 2007 47 Abs V-1919b
83. WHO advisory committee on variola virus research: Report of a WHO meeting. Geneva, Switzerland, 6-9 December 1999. World Health Organization INTERNET SITE 2000 March 20
84. Thermal cycloaddition of maleic-anhydride to cyclohepta-triene, 7h-benzocycloheptene, and 7h-benzo-cycloheptene-7,7-dicarbonitrile. (4-pi + 2-pi) or (2-pi + 2-pi + 2-pi)cycloaddition. Leitich J, Sprintschnik G CHEMISCHE BERICHTE 1986 119 5 1640-1660
85. Smallpox antiviral drug development: Satisfying the animal efficacy rule. Jordan R, Hruby D EXPERT REV ANTI INFECT THER 2006 4 2 277-289
86. Impact of concurrent ST246 administration on ACAM2000 vaccine efficacy in cynomolgus macaques. Silvera PM, Peters E, Bassler J, Gong G, Lin S, Hebblewaite D, Hruby D, Chinsangaram L, Jordan R, Rhodes L ASM BIODEFENSE RES MEET 2009 22 Abs 190 (H) 60B
87. Smallpox. World Health Organization INTERNET SITE 2010 January 19